Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the market to treat metabolic syndrome will nearly double, from $9.5 billion in 2004 to almost $18 billion in 2014.
The new Pharmacor report entitled "Metabolic Syndrome" finds that market growth will be driven by Sanofi-Aventis's Acomplia (rimonabant) and Pfizer's fixed-dose combination of atorvastatin and torcetrapib. In 2014, Acomplia and the combination of atorvastatin and torcetrapib will garner more than $3 billion in sales, accounting for 17% of the total market to treat metabolic syndrome. The report also finds that the creation of a consensus definition of metabolic syndrome remains the greatest unmet need in this indication.
"While we expect this market to grow substantially over the next decade, the achievement of a consensus definition of metabolic syndrome will have broad implications for the future of the market," said Donny Wong, Ph.D., analyst at Decision Resources, Inc. "As the medical community continues to debate the different criteria that define metabolic syndrome, the recent release of similar definitions from the International Diabetes Federation and the American Heart Association marks a key milestone in the growing consensus among physicians."
About Metabolic Syndrome
Metabolic Syndrome is a constellation of comorbidities that includes obesity, diabetes, dyslipidemia, and hypertension. Over time, patients develop a clustering of these comorbidities, which increases the risk of cardiovascular disease.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs currently on the market and in research and development.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/